Effectiveness and safety of Fu’s subcutaneous needling as adjuvant therapy for symptoms after coronavirus disease 2019: a randomized controlled trial

INTERVENTION: Observation group:Basic treatment, including general treatment such as rest, strengthened support treatment, close monitoring of vital signs, oxygen therapy, antibacterial drug treatment, anti COVID‐19 drug treatment, immunotherapy, anticoagulant treatment, prone position treatment, respiratory support, etc,and Fu’s subcutaneous needling;control group:Basic treatment, including general treatment such as rest, strengthened support treatment, close monitoring of vital signs, oxygen therapy, antibacterial drug treatment, anti COVID‐19 drug treatment, immunotherapy, anticoagulant treatment, prone position treatment, respiratory support, etc; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: the cough VAS;Evaluation Scale of Therapeutic Effect of Traditional Chinese Medicine on coronavirus disease 2019 (COVID‐19); SECONDARY OUTCOME: MMrc score;Fatigue Scale‐14,FS‐14;Inflammatory indicators;CT imaging changes;Hospitalization days;7‐day discharge rate; INCLUSION CRITERIA: (1) Conform to diagnostic criteria of coronavirus disease 2019; (2) The age is more than 45 years old and less than 90 years old; (3) Within one month, the patient was newly infected with COVID‐19 and had related clinical symptoms; (4) The vital signs of patients were stable; (5) Sign the informed consent form voluntarily and receive Fus subcutaneous needling.